Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

532 ARTÍCULOS , VIENDO DEL 391 AL 405

Role of Post-translational Modifications in Alzheimer's Disease

Ramesh M, Gopinath P, Govindaraju T.

Chembiochem. 2020 Apr 17;21(8):1052-1079. doi: 10.1002/cbic.201900573. Epub 2020 Jan 30.

[Current Clinical Trials in the Treatment of Alzheimer's Disease]

Tamaoka A.

Brain Nerve. 2020 Jan;72(1):23-34. doi: 10.11477/mf.1416201475.

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease

Wattmo C, Blennow K, Hansson O.

BMC Neurol. 2020 Jan 9;20(1):10. doi: 10.1186/s12883-019-1591-0.

Blood-based Biomarkers of Alzheimer's Disease: The Long and Winding Road

Manzine PR, Vatanabe IP, Peron R, Grigoli MM, Pedroso RV, Nascimento CMC, Cominetti MR.

Curr Pharm Des. 2020;26(12):1300-1315. doi: 10.2174/1381612826666200114105515.

Anti-Amyloid Aggregating Gold Nanoparticles: Can they Really be Translated from Bench to Bedside for Alzheimer's Disease Treatment?

Shaikh S, Nazam N, Danish Rizvi SM, Hussain T, Farhana A, Choi I.

Curr Protein Pept Sci. 2020;21(12):1184-1192. doi: 10.2174/1389203721666200226101930.

Targetting Exosomes as a New Biomarker and Therapeutic Approach for Alzheimer's Disease

Yin Q, Ji X, Lv R, Pei JJ, Du Y, Shen C, Hou X.

Clin Interv Aging. 2020 Feb 13;15:195-205. doi: 10.2147/CIA.S240400. eCollection 2020.

The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease

Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM; Synaptic Health Endpoints Working Group.

Alzheimers Res Ther. 2020 Mar 2;12(1):21. doi: 10.1186/s13195-020-00588-4.

Clinical Experience in Treatment of Alzheimer's Disease with Jiannao Yizhi Formula () and Routine Western Medicine

Wang HC, Liu NY, Zhang S, Yang Y, Wang ZY, Wei Y, Liu JG, Pei H, Li H.

Chin J Integr Med. 2020 Mar;26(3):212-218. doi: 10.1007/s11655-019-2718-2. Epub 2020 Mar 16.

Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer's Disease

Tanaka M, Saito S, Inoue T, Satoh-Asahara N, Ihara M.

Int J Mol Sci. 2020 Mar 14;21(6):1992. doi: 10.3390/ijms21061992.

Functional roles of circular RNAs in Alzheimer's disease

Huang JL, Su M, Wu DP.

Ageing Res Rev. 2020 Jul;60:101058. doi: 10.1016/j.arr.2020.101058. Epub 2020 Mar 29.

Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?

Mullane K, Williams M.

Biochem Pharmacol. 2020 Jul;177:113945. doi: 10.1016/j.bcp.2020.113945. Epub 2020 Apr 2.

New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease

Park SA, Han SM, Kim CE.

Exp Mol Med. 2020 Apr;52(4):556-568. doi: 10.1038/s12276-020-0418-9. Epub 2020 Apr 13.

Proteomics as a reliable approach for discovery of blood-based Alzheimer's disease biomarkers: A systematic review and meta-analysis

Rehiman SH, Lim SM, Neoh CF, Majeed ABA, Chin AV, Tan MP, Kamaruzzaman SB, Ramasamy K.

Ageing Res Rev. 2020 Jul;60:101066. doi: 10.1016/j.arr.2020.101066. Epub 2020 Apr 12.

Early Diagnosis and Targeted Treatment Strategy for Improved Therapeutic Outcomes in Alzheimer's Disease

Guest FL, Rahmoune H, Guest PC.

Adv Exp Med Biol. 2020;1260:175-191. doi: 10.1007/978-3-030-42667-5_8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias